Thomas Bardin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4827982/publications.pdf

Version: 2024-02-01

80 papers	4,447 citations	126708 33 h-index	106150 65 g-index
83 all docs	83 docs citations	83 times ranked	4528 citing authors

#	Article	IF	Citations
1	Serum uric acid and the risk of cardiovascular and renal disease. Journal of Hypertension, 2015, 33, 1729-1741.	0.3	366
2	Definition of hyperuricemia and gouty conditions. Current Opinion in Rheumatology, 2014, 26, 186-191.	2.0	336
3	Gout: An old disease in new perspective â€“ A review. Journal of Advanced Research, 2017, 8, 495-511.	4.4	329
4	Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Annals of the Rheumatic Diseases, 2012, 71, 1839-1848.	0.5	289
5	Gout: why is this curable disease so seldom cured?. Annals of the Rheumatic Diseases, 2012, 71, 1765-1770.	0.5	228
6	2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Annals of the Rheumatic Diseases, 2020, 79, 31-38.	0.5	225
7	Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Medicine, 2017, 15, 123.	2.3	217
8	Improving cardiovascular and renal outcomes in gout: what should we target?. Nature Reviews Rheumatology, 2014, 10, 654-661.	3.5	169
9	An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology, 2009, 48, 711-715.	0.9	168
10	Revisiting comorbidities in gout: a cluster analysis. Annals of the Rheumatic Diseases, 2015, 74, 142-147.	0.5	144
11	Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Annals of the Rheumatic Diseases, 2017, 76, 811-820.	0.5	141
12	Antibiotic Treatment of Venereal Disease and Reiter's Syndrome in a Greenland Population. Arthritis and Rheumatism, 1992, 35, 190-194.	6.7	121
13	Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases. Arthritis Research and Therapy, 2013, 15, R123.	1.6	103
14	Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. BMJ: British Medical Journal, 2019, 364, l67.	2.4	76
15	Discordant American College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nature Reviews Rheumatology, 2017, 13, 561-568.	3.5	74
16	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	1.5	73
17	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.5	72
18	Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1Î² activation on macrophages. Annals of the Rheumatic Diseases, 2020, 79, 1506-1514.	0.5	72

#	Article	IF	Citations
19	Prevalence of Gout in the Adult Population of France. Arthritis Care and Research, 2016, 68, 261-266.	1.5	70
20	Pseudotumor of the craniocervical junction during long-term hemodialysis. Arthritis and Rheumatism, 1990, 33, 1567-1573.	6.7	67
21	Hyperuricemia starts at 360 micromoles (6mg/dL). Joint Bone Spine, 2015, 82, 141-143.	0.8	58
22	Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatologyâ€™s ORA registry. Rheumatology, 2016, 55, 874-882.	0.9	49
23	2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine, 2020, 87, 395-404.	0.8	47
24	Ultrasonography in gout: a case-control study. Clinical and Experimental Rheumatology, 2012, 30, 499-504.	0.4	47
25	A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney International, 2021, 99, 218-226.	2.6	45
26	Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology, 2014, 53, 1920-1926.	0.9	44
27	Spinal involvement with calcium pyrophosphate deposition disease in an academic rheumatology center: A series of 37 patients. Seminars in Arthritis and Rheumatism, 2019, 48, 1113-1126.	1.6	44
28	Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine, 2016, 83, 314-317.	0.8	43
29	Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. Arthritis Care and Research, 2016, 68, 1036-1042.	1.5	40
30	Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice. International Journal of Molecular Sciences, 2020, 21, 4066.	1.8	39
31	An exploratory ultrasound study of early gout. Clinical and Experimental Rheumatology, 2011, 29, 816-21.	0.4	39
32	Six cases of cervical ligamentum flavum calcification in Blacks in the French West Indies. Joint Bone Spine, 2001, 68, 158-165.	0.8	38
33	Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine, 2012, 79, 621-623.	0.8	38
34	Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine, 2017, 84, 595-598.	0.8	37
35	Uric acid and cognitive decline: a double-edge sword?. Current Opinion in Rheumatology, 2018, 30, 183-187.	2.0	37
36	Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study. Rheumatology, 2019, 58, 410-417.	0.9	30

#	Article	IF	Citations
37	Severe gouty arthritis and mild neurologic symptoms due to F199C, a newly identified variant of the hypoxanthine guanine phosphoribosyltransferase. Arthritis and Rheumatism, 2009, 60, 2201-2204.	6.7	29
38	Effectiveness and safety of anakinra in gout patients with stage 4â€“5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine, 2018, 85, 755-760.	0.8	29
39	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. Arthritis Care and Research, 2022, 74, 1649-1658.	1.5	23
40	Cellular Adhesion Gene SELP Is Associated with Rheumatoid Arthritis and Displays Differential Allelic Expression. PLoS ONE, 2014, 9, e103872.	1.1	21
41	The role of febuxostat in gout. Current Opinion in Rheumatology, 2019, 31, 152-158.	2.0	21
42	Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture. Arthritis Research and Therapy, 2018, 20, 78.	1.6	17
43	Renal medulla in severe gout: typical findings on ultrasonography and dual-energy CT study in two patients. Annals of the Rheumatic Diseases, 2019, 78, 433-434.	0.5	17
44	Chondrocalcinosis of the Knee and the Risk of Osteoarthritis Progression: Data From the Knee and Hip Osteoarthritis Longâ€term Assessment Cohort. Arthritis and Rheumatology, 2020, 72, 726-732.	2.9	17
45	2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. Joint Bone Spine, 2020, 87, 387-393.	0.8	17
46	Should prednisolone be first-line therapy for acute gout?. Lancet, The, 2008, 372, 1301.	6.3	16
47	UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis. Joint Bone Spine, 2020, 87, 647-651.	0.8	16
48	Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study. Arthritis Research and Therapy, 2020, 22, 182.	1.6	16
49	A single intra-articular injection of 2.0% non-chemically modified sodium hyaluronate vs 0.8% hylan G-F 20 in the treatment of symptomatic knee osteoarthritis: A 6-month, multicenter, randomized, controlled non-inferiority trial. PLoS ONE, 2019, 14, e0226007.	1.1	15
50	Impact of gender on the response and tolerance to abatacept in patients with rheumatoid arthritis: results from the â€˜ORAâ€™ registry. RMD Open, 2017, 3, e000515.	1.8	14
51	Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5â€‰Years?. Arthritis and Rheumatology, 2022, 74, 1343-1351.	2.9	14
52	Canakinumab for the Patient With Difficult-to-Treat Gouty Arthritis: Review of the Clinical Evidence. Joint Bone Spine, 2015, 82, eS9-eS16.	0.8	13
53	FAST: new look at the febuxostat safety profile. Lancet, The, 2020, 396, 1704-1705.	6.3	13
54	New ACR guidelines for gout management hold some surprises. Nature Reviews Rheumatology, 2013, 9, 9-11.	3.5	12

#	Article	IF	Citations
55	Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. Annals of the Rheumatic Diseases, 2020, 79, 1126-1128.	0.5	11
56	Characterization of copy number variants for CCL3L1 gene in rheumatoid arthritis for French trio families and Tunisian cases and controls. Clinical Rheumatology, 2016, 35, 1917-1922.	1.0	10
57	The Human and Economic Burden of Difficult-to-Treat Gouty Arthritis. Joint Bone Spine, 2015, 82, eS2-eS8.	0.8	9
58	Tendon thickening in dialysis-related joint arthritis is due to amyloid deposits at the surface of the tendon. Joint Bone Spine, 2019, 86, 233-238.	0.8	9
59	Calcium Pyrophosphate Dihydrate Crystal Deposition in Gouty Tophi. Arthritis and Rheumatology, 2021, 73, 324-329.	2.9	9
60	Calcium pyrophosphate crystal deposition in a cohort of 57 patients with Gitelman syndrome. Rheumatology, 2022, 61, 2494-2503.	0.9	8
61	Epidemiology of gout and hyperuricemia in New Caledonia. Joint Bone Spine, 2022, 89, 105286.	0.8	8
62	Chondrolysis of the hip joint in a patient receiving long-term hemodialysis: Histologic and biochemical evaluation. Arthritis and Rheumatism, 1989, 32, 1477-1483.	6.7	7
63	Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al. Annals of the Rheumatic Diseases, 2017, 76, e2-e2.	0.5	7
64	Recommandations de la SociÃ©tÃ© franÃ§aise de rhumatologie pour la prise en charge de la goutteÂ: le traitement hypo-uricÃ©miant. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 332-341.	0.0	5
65	Monosodium urate deposition in the articular cartilage and meniscus can mimic chondrocalcinosis. Joint Bone Spine, 2020, 87, 95-96.	0.8	4
66	Iterative percutaneous needle aponeurotomy for Dupuytren's disease: Functional outcome at 5-year follow-up. Joint Bone Spine, 2020, 87, 273-274.	0.8	4
67	Recommandations 2020Âde la SociÃ©tÃ© franÃ§aise de rhumatologie pour la prise en charge de la goutteÂ: traitement des crises de goutte. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 324-331.	0.0	4
68	Response to: â€˜Uric acid and incident dementia: a population-based cohort studyâ€™ by Lee and Song. Annals of the Rheumatic Diseases, 2018, 77, e63-e63.	0.5	3
69	Shoulder adhesive capsulitis: diagnostic value of active and passive range of motion with volume of gleno-humeral capsule as a reference. European Journal of Physical and Rehabilitation Medicine, 2020, 56, 438-443.	1.1	3
70	The Way Forward: Practical Clinical Considerations for the Use of Canakinumab in Patients With Difficult-to-Treat Gouty Arthritis. Joint Bone Spine, 2015, 82, eS30-eS32.	0.8	2
71	Defining remission in patients with gout. Nature Reviews Rheumatology, 2019, 15, 516-517.	3.5	2
72	Can gout management guidelines be solely evidence based?. Nature Reviews Rheumatology, 2020, 16, 479-480.	3.5	2

#	Article	IF	Citations
73	Distribution of bony erosions in feet and performance of two bone erosion scores: A dual-energy computed tomography study of 61 patients with gout. PLoS ONE, 2021, 16, e0259194.	1.1	2
74	The shrinking toe sign in gout. Seminars in Arthritis and Rheumatism, 2022, 53, 151981.	1.6	2
75	Eosinopenia to differentiate crystal-induced and septic arthritis. Annals of the Rheumatic Diseases, 2022, 81, 1201-1202.	0.5	1
76	SAT0416â€…ULTRASOUND EVALUATION IN FOLLOW-UP OF URATE-LOWERING THERAPY IN GOUT PHASE 2 (USEFUL-2): DURATION OF FLARE PROPHYLAXIS. , 2019, , .		0
77	SAT0412â€…DOES THERAPEUTIC EDUCATION IMPROVE GOUT MANAGEMENT: THE EXPERIENCE OF LARIBOISIERE UNIVERSITY HOSPITAL PARIS-FRANCE. , 2019, , .		0
78	Answer to Checa Â«ÂCoexistence of gout and chondrocalcinosis instead?ÂÂ», Joint Bone Spine 2020. doi:10.1016/j.jbspin.2020.07.007. Joint Bone Spine, 2020, 87, 678-679.	0.8	0
79	Uricaemia as a surrogate endpoint in gout trials and the treat-to-target approach for gout management. Lancet Rheumatology, The, 2021, , .	2.2	0
80	Development of a radiographic scoring system for new bone formation in gout. Arthritis Research and Therapy, 2021, 23, 296.	1.6	0